https://european-biotechnology.com/wp-content/uploads/2024/04/BD.png234445Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-05-18 12:45:322021-05-18 12:45:32BD installs production hub in Zaraogza
Immunoglobin G antibodies (IgG) produced in response to the SARS-CoV-2 spike protein appear to play a role in how COVID-19 can turn more severe in some cases.
https://european-biotechnology.com/wp-content/uploads/2024/04/novel-coronavirus-sars-cov-2_49557785797_o.jpg17162116Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-05-11 17:10:262021-05-11 17:10:26SARS-CoV-2-antibodies may promote severe COVID-19
The Biden administration has announced it will support the WHO proposal to temporarily waive intellectual property rights for COVID-19 vaccines to speed up vaccination.
https://european-biotechnology.com/wp-content/uploads/2024/04/COVshield.jpg9601440Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-05-06 06:41:002021-05-06 06:41:00USA supports to temporarily waive IP of COVID-19 vaccines
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2021-05-06_um_06.30.32.png402662Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-05-06 06:31:002021-05-06 06:31:00Swiss Oculis SA raises $57m in Series C
Cell reprogramming specialist Mogrify Ltd has announced the second closing of its Series A financing of $17m, bringing the total raised to $33m in this round.
https://european-biotechnology.com/wp-content/uploads/2024/04/Mogrify.jpg7502000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-05-04 13:32:332021-05-04 13:32:33Mogrifiy completes Series A financing round
https://european-biotechnology.com/wp-content/uploads/2024/04/Moderna3.Welt.jpeg8531280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-05-03 13:32:422021-05-03 13:32:42COVID-19 vaccine for poor countries
BD installs production hub in Zaraogza
Latest NewsBD will build a €165m manufacturing facility in Zaragoza, Spain to support the growth of its pre-filled drug delivery business.
COVID-19 therapeutics: Germany launches €300m funding
Latest NewsGerman government has launched a €300m programme designed to bring clinically tested COVID-19 treatments to the patient’s bedside.
Recombinant silk producer AMSilk raises €29m
Latest NewsAMSilk GmbH has closed a Series C financing at €29m to accelerate and expand commercialisation of its microbially produced silk fibres.
SARS-CoV-2-antibodies may promote severe COVID-19
Latest NewsImmunoglobin G antibodies (IgG) produced in response to the SARS-CoV-2 spike protein appear to play a role in how COVID-19 can turn more severe in some cases.
Abingworth raises $582m for late-stage fund ACCD 2
Latest NewsInternational life sciences investment group Abingworth has closed a new clinical co-development fund at US$582m.
USA supports to temporarily waive IP of COVID-19 vaccines
Latest NewsThe Biden administration has announced it will support the WHO proposal to temporarily waive intellectual property rights for COVID-19 vaccines to speed up vaccination.
Swiss Oculis SA raises $57m in Series C
Latest NewsTopical ophthalmic therapies developer Oculis S.A. has closed a US$57m Series C financing to push development of its pipeline.
New entrant at Celyad
AppointmentsBelgium-based Celyad has had a new CMO since April: Dr Charles Morris.
Mogrifiy completes Series A financing round
Latest NewsCell reprogramming specialist Mogrify Ltd has announced the second closing of its Series A financing of $17m, bringing the total raised to $33m in this round.
COVID-19 vaccine for poor countries
Latest NewsModerna Inc. has signed a COVID-19 vaccine supply agreement with vaccination alliance Gavi.